Company News & Press Releases

Media professionals who wish to learn more about Theraclone’s technology and areas of research and development, please contact us at:

media@theraclone-sciences.com
206.805.1600

Access recent company press releases via the links below. (Adobe Acrobat Required)

October 6, 2015 MD Anderson, Theraclone Sciences form OncoResponse
April 30, 2015 Theraclone Sciences' I-­‐STAR™ Technology Chosen by Wellcome Trust to Identify Therapeutic Antibodies Against Ebola Virus
July 30, 2014 Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing Antibodies
April 24, 2014 Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies Discovered with Theraclone Technology
December 2, 2013 Theraclone Announces That the Merger Agreement With PharmAthene Has Been Terminated
November 27, 2013 Theraclone Provides Update on BARDA Funding Proposal for TCN-032 for Serious and Pandemic Flu
November 4, 2013 Theraclone Sciences’ Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease
September 11, 2013 Theraclone Sciences Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013
September 10, 2013 Theraclone Sciences Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection
September 8, 2013 Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Total Clinical Symptom Scores and Viral Load in a Phase 2a Human Viral Challenge Study
August 1, 2013 PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
April 2, 2013 Theraclone Sciences Announces Positive Top-line Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection
March 25, 2013 Theraclone Sciences Secures $14 Million in Additional Financing
October 25, 2012 Theraclone Sciences Initiates Phase 2 Viral Challenge Study of Therapeutic Antibody for the Treatment of Influenza A
September 10, 2012 Theraclone Sciences Presents Phase 1 Results of TCN-032, its Therapeutic Antibody Directed at Influenza A, at ICAAC 2012
August 29, 2012 Theraclone Announces Pfizer Selects Next Target in Antibody Discovery Collaboration
June 14, 2012 Theraclone Sciences Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection
May 15, 2012 Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A
December 6, 2011 Theraclone Sciences Announces Appointment of Clifford Stocks as CEO
September 21, 2011 Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A
September 8, 2011 Theraclone Sciences Secures $10.6 Million in Series B Extension Financing
September 6, 2011 Theraclone Sciences Named a 2011 Fierce 15 Biotech by FierceBiotech
August 17, 2011 AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV
January 19, 2011 Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery Collaboration
June 28, 2010 Theraclone Sciences Technology Uncovers Rare Anti-Influenza Antibodies
March 22, 2010 Zenyaku Kogyo Obtains Exclusive License in Japan to Theraclone's Influenza Monoclonal Antibody Program
October 4, 2009 Theraclone and Zenyaku Kogyo Announce Influenza Antibody Alliance
September 3, 2009 Two New Antibodies Found to Cripple HIV
July 6, 2009 IAVI and Theraclone Expand HIV Antibody Discovery Collaboration
March 30, 2009 Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.
March 16, 2007 Spaltudaq Corp Raises $29 Million: Second Accelerator Company to Complete Series B Financing
January 24, 2005 Spaltudaq Corp becomes third biotech company started by Accelerator
May 23, 2007 Spaltudaq Names New Senior Executives